Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000^th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing connective tissue diseases (CTD) and other autoimmune conditions.